Skip to main content
OpenTrials
Completed

NCT Number: NCT02856074

Functional Prognosis in Patients With Ischemic Stroke According to the Therapeutic Strategy Used

The current management of ischemic stroke is based on different strategies that may be combined: intravenous thrombolysis in a stroke ICU, intravenous thrombolysis in a telemedicine procedure, endovascular thrombectomy. Given this now rich therapeutic arsenal, it seems necessary to evaluate practices in local care in the field and the impact of these on the prognosis of ischemic stroke victims. The aim of this observational study is to compare these different care practices without interfering with the choice of strategy.

A blood sample will also be taken at different times to study the value of growth differentiation factors (GDF) 8, 11 and 15, and Brain-derived Neurotrophic Factor as prognostic biomarkers

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Ischemic Stroke Brain Diseases Cardiovascular Diseases Central Nervous System Diseases Cerebrovascular Disorders Nervous System Diseases Stroke Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

CHU Dijon Bourgogne

Dijon, 21079, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with symptomatic ischemic stroke defined according to WHO criteria and treated by intravenous thrombolysis at the stroke ICU at Dijon CHU, intravenous thrombolysis by telemedicine with subsequent transfer to the Dijon stroke ICU, and/or endovascular thrombectomy at Dijon CHU)
  • Patients aged over 18 years.
  • Patients who have provided written informed consent to take part in the study.

Exclusion criteria

  • Patients who refuse to take part in the study.
  • Subjects in custody.
  • Patients (or a person of trust) who cannot be contacted by telephone during the follow-up.

Treatment and study plan

Prise de sang

Biological

Quality of Life Questionnaire

Other

Primary outcomes

  1. Rate of handicap

    Time frame: 6 months

Secondary outcomes

  1. Serum levels of biomarkers of stress

    Time frame: Changes compared with baseline levels at Day 1, Day 3, Day 7

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire Dijon

Other

Registry information

Official study title

Prognosis After Revascularization Therapy in the Dijon Ischemic Stroke Evaluation Study

Acronym: PARADISE

Important dates

Study start
2016
Primary completion
2019
Study completion
2020
First posted
Aug 4, 2016
Registry last updated
Nov 26, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.